Tenaya Therapeutics, Inc. (TNYA) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -105.86M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 61.61M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-105.86M | (m) | (m) | $61.61M | (m) | (m) |
| 2026-03-31 | $-85.86M | (m) | (m) | $62.37M | (m) | (m) |
| 2025-12-31 | $-93.33M | (m) | (m) | $68.61M | (m) | (m) |
| 2025-09-30 | $-97.21M | (m) | (m) | $72.50M | (m) | (m) |
| 2025-06-30 | $-102.98M | (m) | (m) | $77.48M | (m) | (m) |
| 2025-03-31 | $-109.72M | (m) | (m) | $82.76M | (m) | (m) |
| 2024-12-31 | $-115.95M | (m) | (m) | $86.74M | (m) | (m) |
| 2024-09-30 | $-122.74M | (m) | (m) | $90.92M | (m) | (m) |
| 2024-06-30 | $-126.95M | (m) | (m) | $93.66M | (m) | (m) |
| 2024-03-31 | $-131.23M | (m) | (m) | $97.49M | (m) | (m) |
| 2023-12-31 | $-131.19M | (m) | (m) | $98.04M | (m) | (m) |
| 2023-09-30 | $-134.30M | (m) | (m) | $100.92M | (m) | (m) |
| 2023-06-30 | $-134.68M | (m) | (m) | $101.59M | (m) | (m) |
| 2023-03-31 | $-128.19M | (m) | (m) | $95.99M | (m) | (m) |
| 2022-12-31 | $-125.62M | (m) | (m) | $94.54M | (m) | (m) |
| 2022-09-30 | $-117.23M | (m) | (m) | $89.74M | (m) | (m) |
| 2022-06-30 | $-104.24M | (m) | (m) | $78.93M | (m) | (m) |
| 2022-03-31 | $-90.86M | (m) | (m) | $68.96M | (m) | (m) |
| 2021-12-31 | $-72.81M | (m) | (m) | $54.39M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-38.91M | (m) | (m) | $31.10M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |